Physician profile
Hailey Bethune
NPI 1861116188
$3,635.79
in general payments reported to CMS, 2019-2025
31 companies · $998 in 2025
The $998 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $165 · 2023: $1,019 · 2024: $1,453 · 2025: $998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,471.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $529.46 | 2023-2025 | |
| Novo Nordisk INC | $490.10 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $322.71 | 2023-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $263.78 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $231.28 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $192.98 | 2023-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $187.81 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $163.17 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $161.22 | 2023-2024 | Otezla, Repatha, Prolia |
| Astrazeneca Pharmaceuticals Lp | $148.05 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Dexcom, INC. | $131.69 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.18 | 2022-2024 | Jardiance |
| Exact Sciences Corporation | $98.80 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $94.04 | 2023-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $69.47 | 2023-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $55.72 | 2023-2025 | General - Pain Management, Watchman Access System |
| Abbott Laboratories | $46.06 | 2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $43.56 | 2023-2024 | Vpriv |
| Sanofi-Aventis U.S. LLC | $31.94 | 2023-2024 | |
| Surgenex LLC | $29.40 | 2025 | Renograft, Surgraft, Ardeograft |
| Currax Pharmaceuticals LLC | $28.33 | 2023-2024 | Contrave, Onzetra Xsail |
| Daiichi Sankyo INC. | $27.98 | 2023 | Injectafer |
| Seqirus USA INC | $25.48 | 2025 | Flucelvax |
| Hologic Sales and Service, LLC | $24.39 | 2024 | Aptima |
| Esperion Therapeutics, INC. | $24.09 | 2024 | Nexletol |
| Xeris Pharmaceuticals, INC. | $22.83 | 2023 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company Ltd. | $22.34 | 2022 | |
| Medtronic, INC. | $17.97 | 2022 | |
| Ascensia Diabetes Care US INC. | $17.80 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.95 | 2023 | Quviviq |
| Inspire Medical Systems, INC. | $14.21 | 2024 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hailey Bethune listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.